Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$34.2 - $47.13 $85,978 - $118,484
2,514 Added 8.4%
32,430 $1.42 Million
Q4 2023

Feb 13, 2024

BUY
$24.59 - $35.83 $69,319 - $101,004
2,819 Added 10.4%
29,916 $1.06 Million
Q3 2023

Nov 13, 2023

BUY
$21.07 - $29.77 $20,311 - $28,698
964 Added 3.69%
27,097 $731,000
Q2 2023

Aug 04, 2023

BUY
$13.33 - $25.53 $63,397 - $121,420
4,756 Added 22.25%
26,133 $614,000
Q1 2023

May 12, 2023

BUY
$13.49 - $18.72 $5,746 - $7,974
426 Added 2.03%
21,377 $293,000
Q4 2022

Feb 10, 2023

BUY
$14.47 - $18.17 $58,849 - $73,897
4,067 Added 24.09%
20,951 $380,000
Q3 2022

Nov 14, 2022

BUY
$9.24 - $15.79 $2,199 - $3,758
238 Added 1.43%
16,884 $252,000
Q2 2022

Aug 12, 2022

BUY
$8.28 - $13.88 $3,171 - $5,316
383 Added 2.36%
16,646 $230,000
Q1 2022

May 13, 2022

SELL
$11.18 - $24.02 $12,801 - $27,502
-1,145 Reduced 6.58%
16,263 $182,000
Q4 2021

Feb 11, 2022

SELL
$20.95 - $26.88 $10,914 - $14,004
-521 Reduced 2.91%
17,408 $412,000
Q3 2021

Nov 12, 2021

BUY
$17.26 - $27.08 $37,989 - $59,603
2,201 Added 13.99%
17,929 $457,000
Q2 2021

Aug 13, 2021

BUY
$17.76 - $24.83 $96,614 - $135,075
5,440 Added 52.88%
15,728 $330,000
Q1 2021

May 07, 2021

BUY
$13.48 - $23.77 $13,897 - $24,506
1,031 Added 11.14%
10,288 $242,000
Q4 2020

Feb 12, 2021

SELL
$12.17 - $17.52 $3,225 - $4,642
-265 Reduced 2.78%
9,257 $130,000
Q3 2020

Nov 04, 2020

BUY
$11.22 - $14.46 $24,313 - $31,334
2,167 Added 29.46%
9,522 $120,000
Q2 2020

Aug 12, 2020

BUY
$3.59 - $18.57 $26,404 - $136,582
7,355 New
7,355 $105,000

Others Institutions Holding IDYA

About IDEAYA Biosciences, Inc.


  • Ticker IDYA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,067,700
  • Market Cap $1.15B
  • Description
  • IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...
More about IDYA
Track This Portfolio

Track American International Group, Inc. Portfolio

Follow American International Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on American International Group, Inc. with notifications on news.